Qing-Quan Zu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Qing-Quan Zu has a total of 101 co-authors. Here are the top co-authors by number of shared publications:
Sheng Liu
20 shared publicationsJin-Xing Zhang
19 shared publicationsJin Liu
14 shared publicationsHai-Bin Shi
Department of Interventional Radiology, The First Affiliated Hospital with Nanjing Medical University, Nanjing 210029, China (X.S., J-.X.Z., H.-T.Y., S.L., H.-B.S., Q-.Q.Z.).
12 shared publications- Hai-Bin Shi
Department of Interventional Radiology, The First Affiliated Hospital with Nanjing Medical University, Nanjing, China
12 shared publications Hai-Tao Yan
12 shared publications
Latest Publications
- 13 March 2026
- Published by Wiley in Journal of Hepato-Biliary-Pancreatic Sciences
- Vol. 33 (6) , 480-488
Multicenter Comparative Study of Pseudoaneurysm Rupture and Non‐Pseudoaneurysm Hemorrhages Post‐Pancreatectomy
Background: Severe delayed post‐pancreatectomy hemorrhage (SDPPH) is a fatal complication classified into pseudoaneurysm rupture and non‐pseudoaneurysm hemorrhage. This study analyzed their clinical characteristics and outcomes. Methods: A retrospective multicenter cohort study was conducted on consecutive patients who underwent pancreatic resection between January 2014 and December 2023. All SDPPH cases included in the study were confirmed by digital subtraction angiography. Results: Pseudoaneurysm rupture accounted for 47.3% (44/93) of SDPPH. Overall mortality was 29.0% (27/93), without significant difference between the pseudoaneurysm and non‐pseudoaneurysm groups ( p > 0.05). The hemorrhage sites differed significantly between groups, with the common hepatic artery and its branches (excluding gastroduodenal artery) being most frequent in the pseudoaneurysm group (15/44, 34.1%), versus other sites (including anastomosis, splenic artery, portal vein, superior mesenteric vein, and left gastric artery) in the non‐pseudoaneurysm group (22/49, 44.9%). Intensive care unit stay was shorter in the pseudoaneurysm group (1.8 ± 3.9 days) than in the non‐pseudoaneurysm group (5.3 ± 10.6 days; p = 0.040). The clinical hemostasis success was significantly higher in the pseudoaneurysm group (81.8%, 36/44) than in the non‐pseudoaneurysm group (32.7%, 16/49; p < 0.001). Conclusion: Pseudoaneurysm rupture was associated with a better SDPPH prognosis than non‐pseudoaneurysm hemorrhage. Heightened vigilance is warranted for rebleeding in non‐pseudoaneurysm cases.
- 13 March 2026
- Published by Wiley in Journal of Hepato-Biliary-Pancreatic Sciences
- Vol. 33 (6) , 480-488
Multicenter Comparative Study of Pseudoaneurysm Rupture and Non‐Pseudoaneurysm Hemorrhages Post‐Pancreatectomy
Background: Severe delayed post‐pancreatectomy hemorrhage (SDPPH) is a fatal complication classified into pseudoaneurysm rupture and non‐pseudoaneurysm hemorrhage. This study analyzed their clinical characteristics and outcomes. Methods: A retrospective multicenter cohort study was conducted on consecutive patients who underwent pancreatic resection between January 2014 and December 2023. All SDPPH cases included in the study were confirmed by digital subtraction angiography. Results: Pseudoaneurysm rupture accounted for 47.3% (44/93) of SDPPH. Overall mortality was 29.0% (27/93), without significant difference between the pseudoaneurysm and non‐pseudoaneurysm groups ( p > 0.05). The hemorrhage sites differed significantly between groups, with the common hepatic artery and its branches (excluding gastroduodenal artery) being most frequent in the pseudoaneurysm group (15/44, 34.1%), versus other sites (including anastomosis, splenic artery, portal vein, superior mesenteric vein, and left gastric artery) in the non‐pseudoaneurysm group (22/49, 44.9%). Intensive care unit stay was shorter in the pseudoaneurysm group (1.8 ± 3.9 days) than in the non‐pseudoaneurysm group (5.3 ± 10.6 days; p = 0.040). The clinical hemostasis success was significantly higher in the pseudoaneurysm group (81.8%, 36/44) than in the non‐pseudoaneurysm group (32.7%, 16/49; p < 0.001). Conclusion: Pseudoaneurysm rupture was associated with a better SDPPH prognosis than non‐pseudoaneurysm hemorrhage. Heightened vigilance is warranted for rebleeding in non‐pseudoaneurysm cases.
- Open Access
- 1 December 2025
- Published by AME Publishing Company in Journal of Thoracic Disease
- Vol. 17 (12) , 11321-11328
The characteristics of upper lobe-origin hemoptysis: analysis based on 31 patients
Background: Hemoptysis is associated with a variety of respiratory system diseases. Bronchial artery embolization (BAE) is effective for this condition, and preoperative computed tomography angiography (CTA) is helpful for the implementation of BAE. Some non-life-threatening cases have intermittent and recurrent episodes after conservative treatment, and no obvious abnormalities were found during tests and examinations, and they were defined as upper lobe-origin hemoptysis (ULOH), with concerns of embolism. This study aimed to describe the clinical characteristics of a distinct subtype of hemoptysis patients, termed ULOH, as well as the efficacy and outcomes of these patients after BAE. Methods: From April 2019 to March 2024, a total of 31 consecutive ULOH patients who suffered varying episodes of relapse after conservative treatment and then received BAE were included. After the procedure, each case underwent respiratory rehabilitation, followed by dual-energy computed tomography (DECT)to quantitatively assess pulmonary function. Patients’ demographics, clinical characteristics, imaging findings, details of BAE, and outcomes were reviewed and summarized. Results: The median age was 49.0 years old. Twenty-eight patients (90.3%) were male, and 22 (71.0%) cases were heavy smokers. CTA indicated that hemorrhage of alveoli was confined to the upper lobes, and the diameter of all bronchial arteries was no more than 2.0 mm. During bronchial artery angiography, each case showed symmetrical characteristic of systemic-pulmonary shunt (SPS) at bilateral apexes. One month after embolization, chest computed tomography (CT) scan demonstrated complete resolution of the lesion. All patients received 6 months of respiratory rehabilitation after procedures, and the followed integrated analysis of DECT showed structure and function were normal. During a median follow-up period of 24 months, no patient experienced hemoptysis recurrence. Conclusions: Patients with ULOH presented as normal diameter of bronchial arteries and symmetrical characteristic of SPS at bilateral apexes during angiography. After BAE procedure, these patients could harvest complete recovery in both structure and function.
- 1 December 2025
- Published by AME Publishing Company in Journal of Thoracic Disease
- Vol. 17 (12) , 11321-11328
Open AccessThe characteristics of upper lobe-origin hemoptysis: analysis based on 31 patients
Background: Hemoptysis is associated with a variety of respiratory system diseases. Bronchial artery embolization (BAE) is effective for this condition, and preoperative computed tomography angiography (CTA) is helpful for the implementation of BAE. Some non-life-threatening cases have intermittent and recurrent episodes after conservative treatment, and no obvious abnormalities were found during tests and examinations, and they were defined as upper lobe-origin hemoptysis (ULOH), with concerns of embolism. This study aimed to describe the clinical characteristics of a distinct subtype of hemoptysis patients, termed ULOH, as well as the efficacy and outcomes of these patients after BAE. Methods: From April 2019 to March 2024, a total of 31 consecutive ULOH patients who suffered varying episodes of relapse after conservative treatment and then received BAE were included. After the procedure, each case underwent respiratory rehabilitation, followed by dual-energy computed tomography (DECT)to quantitatively assess pulmonary function. Patients’ demographics, clinical characteristics, imaging findings, details of BAE, and outcomes were reviewed and summarized. Results: The median age was 49.0 years old. Twenty-eight patients (90.3%) were male, and 22 (71.0%) cases were heavy smokers. CTA indicated that hemorrhage of alveoli was confined to the upper lobes, and the diameter of all bronchial arteries was no more than 2.0 mm. During bronchial artery angiography, each case showed symmetrical characteristic of systemic-pulmonary shunt (SPS) at bilateral apexes. One month after embolization, chest computed tomography (CT) scan demonstrated complete resolution of the lesion. All patients received 6 months of respiratory rehabilitation after procedures, and the followed integrated analysis of DECT showed structure and function were normal. During a median follow-up period of 24 months, no patient experienced hemoptysis recurrence. Conclusions: Patients with ULOH presented as normal diameter of bronchial arteries and symmetrical characteristic of SPS at bilateral apexes during angiography. After BAE procedure, these patients could harvest complete recovery in both structure and function.
- Open Access
- 28 July 2025
- Published by Springer Nature in Discover Oncology
- Vol. 16 (1) , 1-21
Artificial intelligence-driven pathomics in hepatocellular carcinoma: current developments, challenges and perspectives
Hepatocellular carcinoma (HCC) is a highly malignant tumor with elevated incidence and mortality rates globally. Its complex etiology and pronounced heterogeneity present significant challenges in diagnosis and treatment. Recent advancements in artificial intelligence (AI) have demonstrated transformative potential to usher a new wave of precision oncology. Pathomics, an AI-based digital pathology technique, facilitates the extraction of extensive datasets from whole-slide histopathological images, enabling quantitative analyses to improve diagnosis, treatment, and prognostic prediction for HCC. Furthermore, emerging pathological foundation models are revolutionizing traditional paradigms and providing a robust framework for the development of specialized pathomics models tailored to specific clinical tasks in HCC. Despite its promise, pathomics research in HCC remains in its infancy, with clinical implementation hindered by challenges such as data heterogeneity, model interpretability, ethical concerns, regulatory issues, and the absence of standardized industry protocols. Future initiatives should prioritize the conduction of prospective multi-center studies, the integration of multi-modal data, the enhancement of regulatory frameworks, and the establishment of industry-wide standardized guidelines and compliant platform infrastructures to accelerate the clinical adoption of pathomics for personalized HCC treatment.
- 28 July 2025
- Published by Springer Nature in Discover Oncology
- Vol. 16 (1) , 1-21
Open AccessArtificial intelligence-driven pathomics in hepatocellular carcinoma: current developments, challenges and perspectives
Hepatocellular carcinoma (HCC) is a highly malignant tumor with elevated incidence and mortality rates globally. Its complex etiology and pronounced heterogeneity present significant challenges in diagnosis and treatment. Recent advancements in artificial intelligence (AI) have demonstrated transformative potential to usher a new wave of precision oncology. Pathomics, an AI-based digital pathology technique, facilitates the extraction of extensive datasets from whole-slide histopathological images, enabling quantitative analyses to improve diagnosis, treatment, and prognostic prediction for HCC. Furthermore, emerging pathological foundation models are revolutionizing traditional paradigms and providing a robust framework for the development of specialized pathomics models tailored to specific clinical tasks in HCC. Despite its promise, pathomics research in HCC remains in its infancy, with clinical implementation hindered by challenges such as data heterogeneity, model interpretability, ethical concerns, regulatory issues, and the absence of standardized industry protocols. Future initiatives should prioritize the conduction of prospective multi-center studies, the integration of multi-modal data, the enhancement of regulatory frameworks, and the establishment of industry-wide standardized guidelines and compliant platform infrastructures to accelerate the clinical adoption of pathomics for personalized HCC treatment.
- Open Access
- 1 February 2025
- Published by Taylor & Francis in Journal of Hepatocellular Carcinoma
- Vol. ume 12, 415-426
Increment of Skeletal Muscle Mass Predicts Survival Benefit for Hepatocellular Carcinoma Treated with Transarterial Chemoembolization Combining Molecular Targeted Agents and Immune Checkpoint Inhibitors
Purpose: To assess the relationship between clinical prognosis and changes of skeletal muscle mass for unresectable hepatocellular carcinoma (uHCC) patients who received transarterial chemoembolization (TACE) with molecular-targeted agents and immune checkpoint inhibitors (TACE-MTAs-ICIs). Methods: From June 2019 to June 2023, a total of 92 uHCC patients who received TACE-MTAs-ICIs therapy were included. Skeletal muscle mass was assessed before and 6 months after treatment. Skeletal muscle index (SMI) is calculated as skeletal muscle area at the L3 vertebra divided by the square of height, then the change rate of SMI (ΔSMI) is calculated. Patients were stratified based on ΔSMI as muscle gain and non-muscle gain groups. Overall survival (OS) was compared between groups and prognostic factors for OS were analyzed. Progression-free survival (PFS) was also recorded. Results: The median OS in the muscle gain group was significantly longer than that in the non-muscle gain group (Not reach vs 25.2 months, P < 0.001). The median PFS did not reach significant between two groups (16.2 vs 9.1 months, P = 0.101). Multivariate analyses revealed that skeletal muscle gain (HR = 0.20; 95% CI, 0.06– 0.68; P = 0.010) and Barcelona Clinic Liver Cancer stage (HR = 1.94; 95% CI, 1.02– 3.69; P = 0.044) were independent prognostic factors for OS. Conclusion: SMI increment appeared as a favorable predictor for these uHCC patients who received TACE-MTAs-ICIs therapy.
- 1 February 2025
- Published by Taylor & Francis in Journal of Hepatocellular Carcinoma
- Vol. ume 12, 415-426
Open AccessIncrement of Skeletal Muscle Mass Predicts Survival Benefit for Hepatocellular Carcinoma Treated with Transarterial Chemoembolization Combining Molecular Targeted Agents and Immune Checkpoint Inhibitors
Purpose: To assess the relationship between clinical prognosis and changes of skeletal muscle mass for unresectable hepatocellular carcinoma (uHCC) patients who received transarterial chemoembolization (TACE) with molecular-targeted agents and immune checkpoint inhibitors (TACE-MTAs-ICIs). Methods: From June 2019 to June 2023, a total of 92 uHCC patients who received TACE-MTAs-ICIs therapy were included. Skeletal muscle mass was assessed before and 6 months after treatment. Skeletal muscle index (SMI) is calculated as skeletal muscle area at the L3 vertebra divided by the square of height, then the change rate of SMI (ΔSMI) is calculated. Patients were stratified based on ΔSMI as muscle gain and non-muscle gain groups. Overall survival (OS) was compared between groups and prognostic factors for OS were analyzed. Progression-free survival (PFS) was also recorded. Results: The median OS in the muscle gain group was significantly longer than that in the non-muscle gain group (Not reach vs 25.2 months, P < 0.001). The median PFS did not reach significant between two groups (16.2 vs 9.1 months, P = 0.101). Multivariate analyses revealed that skeletal muscle gain (HR = 0.20; 95% CI, 0.06– 0.68; P = 0.010) and Barcelona Clinic Liver Cancer stage (HR = 1.94; 95% CI, 1.02– 3.69; P = 0.044) were independent prognostic factors for OS. Conclusion: SMI increment appeared as a favorable predictor for these uHCC patients who received TACE-MTAs-ICIs therapy.
- Open Access
- 15 November 2024
- Published by Springer Nature in Research Square
An Explainable machine learning model for predicting response to targeted therapy and immunotherapy in advanced hepatocellular carcinoma: a multicentric study
Background and aims Combination therapy based on targeted therapy and immunotherapy is a first-line treatment for advanced hepatocellular carcinoma (HCC). However, accurately predicting tumor response to the combination therapy is challenging. We aimed to develop an explainable machine learning model to predict response to the combination therapy in advanced HCC. Methods Patients with advanced HCC who received targeted therapy combined with immunotherapy at four tertiary hospitals were enrolled between January 2020 and January 2024. The extreme gradient boosting (XGBoost) model was constructed to predict whether patients would respond to the combination therapy. The area under the receiver operating characteristic curve (AUC) and F1 score were used to evaluate the predictive performance of the XGBoost model. The SHapley Additive exPlanations (SHAP) method was deployed to interpret the XGBoost model. Results A total of 179 patients were enrolled in this study, and seventy-six patients (42.5%) showed a response to the combination therapy. The XGBoost model had an AUC of 0.795 (95% confidence interval: 0.716–0.873) and a F1 score of 0.704 for predicting the response to the combination therapy for advanced HCC in the training set. The importance of SHAP variables in the XGBoost model ranked from high to low, was: interventional therapy, portal vein tumor thrombus, extrahepatic metastasis, number of tumors, and age. Conclusion The XGBoost machine learning model shows high performance in predicting response to targeted therapy combined with immunotherapy in advanced HCC. Additionally, the SHAP method facilitates a comprehensive interpretation of the results generated by the machine learning model.
- 15 November 2024
- Published by Springer Nature in Research Square
Open AccessAn Explainable machine learning model for predicting response to targeted therapy and immunotherapy in advanced hepatocellular carcinoma: a multicentric study
Background and aims Combination therapy based on targeted therapy and immunotherapy is a first-line treatment for advanced hepatocellular carcinoma (HCC). However, accurately predicting tumor response to the combination therapy is challenging. We aimed to develop an explainable machine learning model to predict response to the combination therapy in advanced HCC. Methods Patients with advanced HCC who received targeted therapy combined with immunotherapy at four tertiary hospitals were enrolled between January 2020 and January 2024. The extreme gradient boosting (XGBoost) model was constructed to predict whether patients would respond to the combination therapy. The area under the receiver operating characteristic curve (AUC) and F1 score were used to evaluate the predictive performance of the XGBoost model. The SHapley Additive exPlanations (SHAP) method was deployed to interpret the XGBoost model. Results A total of 179 patients were enrolled in this study, and seventy-six patients (42.5%) showed a response to the combination therapy. The XGBoost model had an AUC of 0.795 (95% confidence interval: 0.716–0.873) and a F1 score of 0.704 for predicting the response to the combination therapy for advanced HCC in the training set. The importance of SHAP variables in the XGBoost model ranked from high to low, was: interventional therapy, portal vein tumor thrombus, extrahepatic metastasis, number of tumors, and age. Conclusion The XGBoost machine learning model shows high performance in predicting response to targeted therapy combined with immunotherapy in advanced HCC. Additionally, the SHAP method facilitates a comprehensive interpretation of the results generated by the machine learning model.
- Open Access
- 1 November 2024
- Published by Taylor & Francis in Annals of Medicine
- Vol. 56 (1) , 2419993
Transarterial chemoembolization combined with molecular targeted agents plus immune checkpoint inhibitors for unresectable hepatocellular carcinoma beyond the up-to-seven criteria: a propensity score-matching analysis
Not all patients benefit from transarterial chemoembolization (TACE) due to the heterogeneity of the tumour burden in intermediate-stage hepatocellular carcinoma (HCC). To compare the outcomes of transarterial chemoembolization (TACE) combined with molecular-targeted agents plus immune checkpoint inhibitors (TACE-MTAs-ICIs) with those of TACE for patients with unresectable hepatocellular carcinoma (uHCC) that were beyond the up-to-seven criteria. Between January 2019 and July 2022, 130 patients diagnosed with uHCC beyond the up-to-seven criteria were retrospectively identified, including 47 patients who received TACE-MTAs-ICIs and 83 patients who received TACE alone. The primary endpoints were overall survival (OS) and progression-free survival (PFS); the secondary endpoints included tumour response and adverse events (AEs). There were 43 matched patients. The median OS and PFS times in the TACE-MTAs-ICIs group were significantly longer than those in the TACE group (OS: 27.2 vs. 15.9 months, p = 0.007; PFS: 15.4 months vs. 4.8 months, p < 0.001). The objective response rate (ORR) in the TACE-MTAs-ICIs group was higher than that in the TACE group (65.1% vs. 37.2%, p = 0.010). Reversible AEs (grade 3 or 4) occurred differently in TACE-MTAs-ICIs and TACE groups (83.7% vs. 51.2%, p = 0.001). Univariate and multivariate analyses revealed that TACE-MTAs-ICIs treatment was an independent favourable prognostic factor for both PFS and OS (p < 0.001). For uHCC patients beyond the up-to-seven criteria, TACE-MTAs-ICIs provided superior ORR and OS. Early combined TACE and systemic treatment should shift for patients who are beyond these criteria.
- 1 November 2024
- Published by Taylor & Francis in Annals of Medicine
- Vol. 56 (1) , 2419993
Open AccessTransarterial chemoembolization combined with molecular targeted agents plus immune checkpoint inhibitors for unresectable hepatocellular carcinoma beyond the up-to-seven criteria: a propensity score-matching analysis
Not all patients benefit from transarterial chemoembolization (TACE) due to the heterogeneity of the tumour burden in intermediate-stage hepatocellular carcinoma (HCC). To compare the outcomes of transarterial chemoembolization (TACE) combined with molecular-targeted agents plus immune checkpoint inhibitors (TACE-MTAs-ICIs) with those of TACE for patients with unresectable hepatocellular carcinoma (uHCC) that were beyond the up-to-seven criteria. Between January 2019 and July 2022, 130 patients diagnosed with uHCC beyond the up-to-seven criteria were retrospectively identified, including 47 patients who received TACE-MTAs-ICIs and 83 patients who received TACE alone. The primary endpoints were overall survival (OS) and progression-free survival (PFS); the secondary endpoints included tumour response and adverse events (AEs). There were 43 matched patients. The median OS and PFS times in the TACE-MTAs-ICIs group were significantly longer than those in the TACE group (OS: 27.2 vs. 15.9 months, p = 0.007; PFS: 15.4 months vs. 4.8 months, p < 0.001). The objective response rate (ORR) in the TACE-MTAs-ICIs group was higher than that in the TACE group (65.1% vs. 37.2%, p = 0.010). Reversible AEs (grade 3 or 4) occurred differently in TACE-MTAs-ICIs and TACE groups (83.7% vs. 51.2%, p = 0.001). Univariate and multivariate analyses revealed that TACE-MTAs-ICIs treatment was an independent favourable prognostic factor for both PFS and OS (p < 0.001). For uHCC patients beyond the up-to-seven criteria, TACE-MTAs-ICIs provided superior ORR and OS. Early combined TACE and systemic treatment should shift for patients who are beyond these criteria.
- Open Access
- 1 October 2024
- Published by Taylor & Francis in Journal of Hepatocellular Carcinoma
- Vol. ume 11, 1993-2003
Efficacy of Atezolizumab Plus Bevacizumab Combined with Transarterial Chemoembolization for Unresectable Hepatocellular Carcinoma: A Real-World Study
Purpose: Transarterial chemoembolization (TACE), when used in combination with immunotherapy and antiangiogenic therapy, has been shown to have synergistic anticancer effects. The aim of this study was to further assess the efficacy and safety of TACE combined with atezolizumab and bevacizumab in the treatment of unresectable hepatocellular carcinoma (HCC) in the real world. Methods: Between August 2021 and September 2023, clinical information was collected from consecutive HCC patients who received treatment via TACE-Atezo/Bev at four tertiary institutions. This study evaluated the objective response rate (ORR), overall survival (OS), and progression-free survival (PFS) as outcomes. Predictors for OS and PFS were also analyzed. Treatment-related adverse events (TRAEs) were recorded and assessed. Results: Ninety-two patients were enrolled in this study, with a median follow-up duration of 14.1 months. The ORRs based on the modified Response Evaluation Criteria in Solid Tumors (RECIST) and RECIST 1.1 criteria were 54.3% and 41.3%, respectively. The median OS and PFS of the patients were 15.9 months [95% confidence interval (CI), 14.5– 17.2 months] and 9.1 months (95% CI, 7.4– 10.8 months), respectively. Multivariate analyses revealed that the Eastern Cooperative Oncology Group score and neutrophil‒lymphocyte ratio were independent risk factors for OS, whereas tumor size and extrahepatic metastasis were independent risk factors for PFS. Grade 3/4 TRAEs occurred in 16.3% (15/92) of the patients and were controlled conservatively. Conclusion: The combination of Atezo/Bev with TACE demonstrated acceptable synergistic therapeutic effects and manageable safety profiles in patients with unresectable HCC.
- 1 October 2024
- Published by Taylor & Francis in Journal of Hepatocellular Carcinoma
- Vol. ume 11, 1993-2003
Open AccessEfficacy of Atezolizumab Plus Bevacizumab Combined with Transarterial Chemoembolization for Unresectable Hepatocellular Carcinoma: A Real-World Study
Purpose: Transarterial chemoembolization (TACE), when used in combination with immunotherapy and antiangiogenic therapy, has been shown to have synergistic anticancer effects. The aim of this study was to further assess the efficacy and safety of TACE combined with atezolizumab and bevacizumab in the treatment of unresectable hepatocellular carcinoma (HCC) in the real world. Methods: Between August 2021 and September 2023, clinical information was collected from consecutive HCC patients who received treatment via TACE-Atezo/Bev at four tertiary institutions. This study evaluated the objective response rate (ORR), overall survival (OS), and progression-free survival (PFS) as outcomes. Predictors for OS and PFS were also analyzed. Treatment-related adverse events (TRAEs) were recorded and assessed. Results: Ninety-two patients were enrolled in this study, with a median follow-up duration of 14.1 months. The ORRs based on the modified Response Evaluation Criteria in Solid Tumors (RECIST) and RECIST 1.1 criteria were 54.3% and 41.3%, respectively. The median OS and PFS of the patients were 15.9 months [95% confidence interval (CI), 14.5– 17.2 months] and 9.1 months (95% CI, 7.4– 10.8 months), respectively. Multivariate analyses revealed that the Eastern Cooperative Oncology Group score and neutrophil‒lymphocyte ratio were independent risk factors for OS, whereas tumor size and extrahepatic metastasis were independent risk factors for PFS. Grade 3/4 TRAEs occurred in 16.3% (15/92) of the patients and were controlled conservatively. Conclusion: The combination of Atezo/Bev with TACE demonstrated acceptable synergistic therapeutic effects and manageable safety profiles in patients with unresectable HCC.
- 26 April 2024
- Published by Springer Nature in CardioVascular and Interventional Radiology
- Vol. 47 (6) , 751-761
Transarterial Chemoembolization Combined with Tyrosine Kinase Inhibitors Plus Immune Checkpoint Inhibitors Versus Tyrosine Kinase Inhibitors Plus Immune Checkpoint Inhibitors in Unresectable Hepatocellular Carcinoma with First- or Lower-Order Portal Vein Tumor Thrombosis
Purpose To compare the efficacy of transarterial chemoembolization (TACE) combined with tyrosine kinase inhibitors (TKIs) plus immune checkpoint inhibitors (ICIs) (TACE-TKI-ICI) versus TKIs plus ICIs (TKI-ICI) for unresectable hepatocellular carcinoma (HCC) with first- or lower-order portal vein tumor thrombosis (PVTT). Materials and Methods A retrospective study was performed in HCC patients with first- or lower-order PVTT receiving TKIs (Lenvatinib or sorafenib) plus ICIs (camrelizumab, sintilimab, or atezolizumab) with or without TACE from four institutions between January 2019 and January 2022. Propensity score–based method was performed to minimize bias by confounding factors. Tumor response, progression-free survival (PFS), overall survival (OS), and adverse events (AEs) were evaluated and compared between the two groups. Results After inverse probability of treatment weighting, two balanced pseudopopulations were created: 106 patients in the TACE-TKI-ICI group and 109 patients in the TKI-ICI group. The objective response rate was higher in the TACE-TKI-ICI group (50.9% vs. 28.4%, P < 0.001). The median PFS and OS were significantly longer in the TACE-TKI-ICI group than in the TKI-ICI group (PFS: 9.1 vs. 5.0 months, P = 0.005; OS: 19.1 vs. 12.7 months, P = 0.002). In Cox regression, TACE-TKI-ICI treatment was an independent predictor of favorable OS. Treatment-related grade 3/4 AEs were comparable between the two groups (22.6% vs. 17.9%, P = 0.437). Conclusion TACE-TKI-ICI therapy contributed to better tumor control, PFS and OS than TKI-ICI therapy in unresectable HCC patients with first- or lower-order PVTT. Graphical Abstract
- 26 April 2024
- Published by Springer Nature in CardioVascular and Interventional Radiology
- Vol. 47 (6) , 751-761
Transarterial Chemoembolization Combined with Tyrosine Kinase Inhibitors Plus Immune Checkpoint Inhibitors Versus Tyrosine Kinase Inhibitors Plus Immune Checkpoint Inhibitors in Unresectable Hepatocellular Carcinoma with First- or Lower-Order Portal Vein Tumor Thrombosis
Purpose To compare the efficacy of transarterial chemoembolization (TACE) combined with tyrosine kinase inhibitors (TKIs) plus immune checkpoint inhibitors (ICIs) (TACE-TKI-ICI) versus TKIs plus ICIs (TKI-ICI) for unresectable hepatocellular carcinoma (HCC) with first- or lower-order portal vein tumor thrombosis (PVTT). Materials and Methods A retrospective study was performed in HCC patients with first- or lower-order PVTT receiving TKIs (Lenvatinib or sorafenib) plus ICIs (camrelizumab, sintilimab, or atezolizumab) with or without TACE from four institutions between January 2019 and January 2022. Propensity score–based method was performed to minimize bias by confounding factors. Tumor response, progression-free survival (PFS), overall survival (OS), and adverse events (AEs) were evaluated and compared between the two groups. Results After inverse probability of treatment weighting, two balanced pseudopopulations were created: 106 patients in the TACE-TKI-ICI group and 109 patients in the TKI-ICI group. The objective response rate was higher in the TACE-TKI-ICI group (50.9% vs. 28.4%, P < 0.001). The median PFS and OS were significantly longer in the TACE-TKI-ICI group than in the TKI-ICI group (PFS: 9.1 vs. 5.0 months, P = 0.005; OS: 19.1 vs. 12.7 months, P = 0.002). In Cox regression, TACE-TKI-ICI treatment was an independent predictor of favorable OS. Treatment-related grade 3/4 AEs were comparable between the two groups (22.6% vs. 17.9%, P = 0.437). Conclusion TACE-TKI-ICI therapy contributed to better tumor control, PFS and OS than TKI-ICI therapy in unresectable HCC patients with first- or lower-order PVTT. Graphical Abstract
- 12 March 2024
- Published by Springer Nature in Journal of Gastrointestinal Cancer
- Vol. 55 (2) , 1-8
Efficacy and Safety of TACE Combined with a Tyrosine Kinase Inhibitor for the Treatment of TACE-Refractory Hepatocellular Carcinoma: A Retrospective Comparative Study
Purpose Combining angiogenesis inhibitors may enhance therapeutic efficacy synergistically after TACE refractoriness. The purpose of this study was to compare the outcomes of transarterial chemoembolization (TACE) plus a tyrosine kinase inhibitor (TACE-TKI) with TKI only for patients with TACE-refractory hepatocellular carcinoma (HCC). Methods From January 2019 to March 2022, 101 HCC patients confirmed with TACE-refractory were retrospectively reviewed in the study. Progression-free survival (PFS), overall survival (OS), tumor response, and adverse events (AEs) were evaluated between groups. Results Fifty-two patients undergoing TACE-TKI, while 32 patients receiving TKI alone were included. The objective response rate (ORR) was higher in the TACE-TKI group compared with the TKI group (55.8% vs. 25.0%, P = 0.006). The median PFS in the TACE-TKI group was significantly longer than that in the TKI group (7.6 months vs. 4.9 months, P = 0.018). The median OS was non reach to statistical longer than that in the TKI alone group (19.5 months vs. 17.7 months, P = 0.055). Subgroup analysis showed that TACE-TKI treatment resulted in a significantly longer median PFS and OS for Barcelona Clinic Liver Cancer (BCLC) stage B patients (PFS 11.8 months vs. 5.1 months, P = 0.017; OS 30.3 months vs. 19.4 months, P = 0.022). Conclusion For patients with TACE-refractory HCC, TACE-TKI appeared to be superior to TKI monotherapy with regard to tumor control and PFS. Furthermore, for the BCLC stage B subgroup, TACE-TKI therapy was superior to TKI monotherapy in both OS and PFS.
- 12 March 2024
- Published by Springer Nature in Journal of Gastrointestinal Cancer
- Vol. 55 (2) , 1-8
Efficacy and Safety of TACE Combined with a Tyrosine Kinase Inhibitor for the Treatment of TACE-Refractory Hepatocellular Carcinoma: A Retrospective Comparative Study
Purpose Combining angiogenesis inhibitors may enhance therapeutic efficacy synergistically after TACE refractoriness. The purpose of this study was to compare the outcomes of transarterial chemoembolization (TACE) plus a tyrosine kinase inhibitor (TACE-TKI) with TKI only for patients with TACE-refractory hepatocellular carcinoma (HCC). Methods From January 2019 to March 2022, 101 HCC patients confirmed with TACE-refractory were retrospectively reviewed in the study. Progression-free survival (PFS), overall survival (OS), tumor response, and adverse events (AEs) were evaluated between groups. Results Fifty-two patients undergoing TACE-TKI, while 32 patients receiving TKI alone were included. The objective response rate (ORR) was higher in the TACE-TKI group compared with the TKI group (55.8% vs. 25.0%, P = 0.006). The median PFS in the TACE-TKI group was significantly longer than that in the TKI group (7.6 months vs. 4.9 months, P = 0.018). The median OS was non reach to statistical longer than that in the TKI alone group (19.5 months vs. 17.7 months, P = 0.055). Subgroup analysis showed that TACE-TKI treatment resulted in a significantly longer median PFS and OS for Barcelona Clinic Liver Cancer (BCLC) stage B patients (PFS 11.8 months vs. 5.1 months, P = 0.017; OS 30.3 months vs. 19.4 months, P = 0.022). Conclusion For patients with TACE-refractory HCC, TACE-TKI appeared to be superior to TKI monotherapy with regard to tumor control and PFS. Furthermore, for the BCLC stage B subgroup, TACE-TKI therapy was superior to TKI monotherapy in both OS and PFS.